PRINCETON, N.J., May 17, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
| Event: | Advaxis Investor & Analyst Day | |
| Date: | Tuesday, June 28, 2016 | |
| Time: | 1:30 – 4:30 PM EST, Reception from 4:30 – 5:30 PM | |
| Location: | Offices of Reed Smith | |
| 599 Lexington Avenue, 22nd Floor | ||
| New York, NY 10022 |
Registration is required to attend the event. To register, please visit: www.advaxis.com.
The Investor & Analyst Day will be exclusively led by the investigators on Advaxis’ clinical programs. The investigators will present data and other scientific insights on the lead immunotherapy candidate, axalimogene filolisbac (AXAL), in HPV-associated cancers (cervical, anal, and head and neck), ADXS-PSA in prostate cancer, and ADXS-NEO, the Company’s customized neo-epitope immunotherapy.
Some of the clinical investigators that are expected to participate in the event include:
- Bradley Monk, M.D. is the Director of the Division of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center. Dr. Monk is the Lead Cervical Cancer Advisor to Advaxis, and is a key contributor to the development of the planned Phase 3 AIM2CERV trial.
- Warner K. Huh, M.D. is a professor and Division Director of Gynecologic Oncology and Senior Scientist at the University of Alabama in Birmingham. Dr. Huh is the lead investigator of GOG-0265, a Phase 2 clinical study evaluating the potential of AXAL as an immunotherapy for patients with pre-treated metastatic cervical cancer. Data from this study was selected for a presentation at the American Society of Clinical Oncology (ASCO).
- Nashat Gabrail, M.D. is an oncologist at the Gabrail Cancer Center in Canton, Ohio. Dr. Gabrail is the principal investigator in a study evaluating AXAL in combination with MedImmune’s durvalumab, which is currently in its second dose-escalation phase.
- Brian Slomovitz, M.D. is the Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Miami Miller School of Medicine, as well as Co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center. Dr. Slomovitz is an investigator evaluating AXAL in combination with durvalumab, which is currently in its second dose-escalation phase.
- Howard Safran, M.D. is the Director of the Brown University Oncology Group and Associate Professor of Medicine at the Warren Alpert Medical School at the University. Dr. Safran is the principal investigator for a Phase 1/2 clinical trial evaluating AXAL in HPV-associated locally advanced anal cancer.
- Lisa Kachnic, M.D. is the Associate Director of Multidisciplinary Cancer Research at Boston University and Professor and Chair of Radiation Oncology at Vanderbilt University. Dr. Kachnic plans to evaluate AXAL in a registration quality study in HPV-associated anal cancer.
- Mark Stein, M.D. is a medical oncologist at the Cancer Institute of New Jersey, specializing in prostate cancer. Dr. Stein is an investigator in a Phase 1/2 trial evaluating AXAL in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer- fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology™ immunotherapy, axalimogene filolisbac (AXAL), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted AXAL orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products in human clinical development: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors.
For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.
Advaxis Forward-Looking Statement
This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
CONTACTS:
Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.250.7515
Media Contact:
JPA Health Communications
Nic DiBella
Nic@jpa.com
617.945.5183
